|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
GLOBULIN AND IMMUNE (HUMAN)"
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Agammaglobulinemia |
|
Hepatitis A, prophylaxis |
|
Hypogammaglobulinemia |
|
Immunization, rubeola |
|
Immunoglobulin deficiency |
|
Varicella, passive immunity |
| |
|
|
SIDE EFFECTS:
|
|
Chest or hip pain |
|
leg cramps |
|
redness, rash, or pain at injection site |
|
urticaria |
|
Except under special circumstances, this medication should not be used when the following medical problems exist |
|
Risk-benefit should be considered when the following medical problems exist |
|
Dyspnea |
|
tachycardia |
|
Burning sensation in head |
|
cyanosis |
|
faintness or lightheadedness |
|
fatigue |
|
wheezing |
|
Anaphylactic reaction |
|
Arthralgia |
|
backache or pain |
|
headache |
|
malaise |
|
myalgia |
|
nausea |
|
vomiting |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Cardiac function impairment in seriously ill patients |
|
Diabetes mellitus |
|
>> Renal failure, acute |
|
Sensitivity to immune globulins |
|
Sensitivity to maltose or sucrose |
|
|
ADULT DOSE:
|
|
Immunodeficiency, primary (treatment) -
Intravenous, initially, 200 to 400 mg per kg of body weight once a month .
Idiopathic thrombocytopenic purpura (ITP) (treatment)-
Intravenous, 400 mg per kg of body weight per day for two to five consecutive days. If the patient"s response is inadequate, 400 mg per kg of body weight may be administered as a single maintenance dose once every several weeks. In some patients, it may be necessary to increase the maintenance dose up to 800 mg or 1 gram per kg of body weight.
Bacterial infections secondary to B-cell chronic lymphocytic leukemia (CLL) (treatment adjunct) -
Intravenous, 400 mg per kg of body weight once every three to four weeks.
Kawasaki disease (treatment adjunct)-
Intravenous, a single dose of 2 grams per kg of body weight may be administered .
Because all studies have involved concurrent administration of aspirin, the treatment regimen should include aspirin, 100 mg per kg of body weight each day, until fever defervesces , then 3 to 5 mg per kg of body weight as a single daily dose for six to eight weeks if coronary artery abnormalities are not detected .
[Dermatomyositis (treatment)] -
Intravenous, 1 gram per kg of body weight for two days per month for three months .
[Guillain-Barre syndrome (GBS) (treatment)] -
Intravenous, 400 mg per kg of body weight a day for five days .
[Hyperimmunoglobulinemia E syndrome (treatment)] -
Intravenous, 400 mg per kg of body weight a day for five days .
[Lambert-Eaton myasthenic syndrome (treatment)] -
Intravenous, 1 gram per kg of body weight a day for two consecutive days .
[Multifocal motor neuropathy (MMN) (treatment)] -
Intravenous, 400 mg per kg of body weight a day for five days .
[Multiple sclerosis, relapsing-remitting (treatment)] -
Intravenous, 200 mg per kg of body weight a month for two years .
[Parvovirus B19 infection, chronic (treatment)] -
Intravenous, 400 mg per kg of body weight per day for five days followed by twice a week for two weeks . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Immunodeficiency, primary (treatment) -
Intravenous, initially, 200 to 400 mg per kg of body weight once a month .
Idiopathic thrombocytopenic purpura (ITP) (treatment)-
Intravenous, 400 mg per kg of body weight per day for two to five consecutive days. If the patient"s response is inadequate, 400 mg per kg of body weight may be administered as a single maintenance dose once every several weeks. In some patients, it may be necessary to increase the maintenance dose up to 800 mg or 1 gram per kg of body weight.
Bacterial infections secondary to B-cell chronic lymphocytic leukemia (CLL) (treatment adjunct) -
Intravenous, 400 mg per kg of body weight once every three to four weeks.
Kawasaki disease (treatment adjunct)-
Intravenous, a single dose of 2 grams per kg of body weight may be administered .
Because all studies have involved concurrent administration of aspirin, the treatment regimen should include aspirin, 100 mg per kg of body weight each day, until fever defervesces , then 3 to 5 mg per kg of body weight as a single daily dose for six to eight weeks if coronary artery abnormalities are not detected .
[Dermatomyositis (treatment)] -
Intravenous, 1 gram per kg of body weight for two days per month for three months .
[Guillain-Barre syndrome (GBS) (treatment)] -
Intravenous, 400 mg per kg of body weight a day for five days .
[Hyperimmunoglobulinemia E syndrome (treatment)] -
Intravenous, 400 mg per kg of body weight a day for five days .
[Lambert-Eaton myasthenic syndrome (treatment)] -
Intravenous, 1 gram per kg of body weight a day for two consecutive days .
[Multifocal motor neuropathy (MMN) (treatment)] -
Intravenous, 400 mg per kg of body weight a day for five days .
[Multiple sclerosis, relapsing-remitting (treatment)] -
Intravenous, 200 mg per kg of body weight a month for two years .
[Parvovirus B19 infection, chronic (treatment)] -
Intravenous, 400 mg per kg of body weight per day for five days followed by twice a week for two weeks . |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|